LON:AREC Arecor Therapeutics Final Earnings Results & Report GBX 72 -4.00 (-5.26%) As of 11/20/2026 09:56 AM Eastern Arecor Therapeutics reported Final earnings on April 13, 2026. The company reported EPS of GBX 2, while revenue was £1.71 million. Research:ProfileEarnings History Earnings Announcement Details QuarterFinalReport DateApril 13, 2026TimeBefore Market Opens Arecor Therapeutics EPS ResultsActual EPSGBX 2Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AArecor Therapeutics Revenue ResultsActual Revenue£1.71 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Arecor Therapeutics Final Earnings FAQ Did Arecor Therapeutics beat earnings estimates for Final? Arecor Therapeutics (LON:AREC) reported earnings of GBX 2 per share for Final. The report was announced on Monday, April 13, 2026. What was Arecor Therapeutics' revenue for Final? Arecor Therapeutics reported revenue of £1.71 million for Final. Arecor Therapeutics Earnings HeadlinesArecor Therapeutics PLCNovember 18, 2026 | marketwatch.comArecor Therapeutics Plc Strengthens Patent Protection For Its Proprietary AT278 ProductOctober 16, 2026 | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 22 at 1:00 AM | Base Camp Trading (Ad)Patents for concentrated ultra-rapid insulinsOctober 15, 2026 | markets.ft.comAnglo Asian Mining, Quantum Helium, Quadrise, Arecor Therapeutics - Small Cap SnapshotOctober 15, 2026 | finance.yahoo.comArecor Therapeutics adds patents as it eyes $3 billion US marketOctober 15, 2026 | uk.finance.yahoo.comSee More Arecor Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arecor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arecor Therapeutics and other key companies, straight to your email. Email Address About Arecor TherapeuticsArecor Therapeutics (LON:AREC) (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion-dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.View Arecor Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20Keysight Technologies: The Tollbooth on the Technology SuperhighwayGrowing Pains Versus Growth: Is BJ’s Wholesale Club a Buying Opportunity?Bargain Hunting: Why Off-Price Retail Is WinningZscaler Got a Boost From Palo Alto, But Now It Has to Deliver.If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.